vs
NOVAVAX INC（NVAX）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是NOVAVAX INC的1.4倍（$200.5M vs $147.3M），NOVAVAX INC净利率更高（11.9% vs 2.2%，领先9.7%），NOVAVAX INC同比增速更快（66.8% vs 5.2%），ROGERS CORP自由现金流更多（$1.1M vs $-41.6M），过去两年NOVAVAX INC的营收复合增速更高（25.3% vs -3.3%）
诺瓦瓦克斯是一家总部位于美国马里兰州盖瑟斯堡的生物科技企业，专注于传染病疫苗研发。其开发的新冠疫苗现由赛诺菲负责商业化，同时还在布局流感、呼吸道合胞病毒（RSV）、禽流感、带状疱疹、艰难梭菌感染、疟疾等多个领域的疫苗管线。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
NVAX vs ROG — 直观对比
营收规模更大
ROG
是对方的1.4倍
$147.3M
营收增速更快
NVAX
高出61.6%
5.2%
净利率更高
NVAX
高出9.7%
2.2%
自由现金流更多
ROG
多$42.7M
$-41.6M
两年增速更快
NVAX
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $147.3M | $200.5M |
| 净利润 | $17.5M | $4.5M |
| 毛利率 | 85.0% | 32.2% |
| 营业利润率 | 9.7% | — |
| 净利率 | 11.9% | 2.2% |
| 营收同比 | 66.8% | 5.2% |
| 净利润同比 | 121.6% | 421.4% |
| 每股收益（稀释后） | $0.28 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NVAXROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $147.3M | $201.5M | ||
| Q3 25 | $70.4M | $216.0M | ||
| Q2 25 | $239.2M | $202.8M | ||
| Q1 25 | $666.5M | $190.5M | ||
| Q4 24 | $88.3M | $192.2M | ||
| Q3 24 | $84.5M | $210.3M | ||
| Q2 24 | $415.5M | $214.2M |
净利润NVAXROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $17.5M | $4.6M | ||
| Q3 25 | $-202.4M | $8.6M | ||
| Q2 25 | $106.5M | $-73.6M | ||
| Q1 25 | $518.6M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-121.3M | $10.7M | ||
| Q2 24 | $162.4M | $8.1M |
毛利率NVAXROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 85.0% | 31.5% | ||
| Q3 25 | 69.5% | 33.5% | ||
| Q2 25 | 93.6% | 31.6% | ||
| Q1 25 | 97.9% | 29.9% | ||
| Q4 24 | 58.5% | 32.1% | ||
| Q3 24 | 28.3% | 35.2% | ||
| Q2 24 | 88.9% | 34.1% |
营业利润率NVAXROG
| Q1 26 | — | — | ||
| Q4 25 | 9.7% | 3.5% | ||
| Q3 25 | -252.7% | 7.3% | ||
| Q2 25 | 42.2% | -33.3% | ||
| Q1 25 | 77.4% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | -158.6% | 6.9% | ||
| Q2 24 | 38.7% | 5.3% |
净利率NVAXROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 11.9% | 2.3% | ||
| Q3 25 | -287.3% | 4.0% | ||
| Q2 25 | 44.5% | -36.3% | ||
| Q1 25 | 77.8% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -143.5% | 5.1% | ||
| Q2 24 | 39.1% | 3.8% |
每股收益（稀释后）NVAXROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.28 | $0.20 | ||
| Q3 25 | $-1.25 | $0.48 | ||
| Q2 25 | $0.62 | $-4.00 | ||
| Q1 25 | $2.93 | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | $-0.76 | $0.58 | ||
| Q2 24 | $0.99 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $735.1M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-127.8M | $1.2B |
| 总资产 | $1.2B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NVAXROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $735.1M | $197.0M | ||
| Q3 25 | $762.9M | $167.8M | ||
| Q2 25 | $612.3M | $157.2M | ||
| Q1 25 | $731.5M | $175.6M | ||
| Q4 24 | $923.1M | $159.8M | ||
| Q3 24 | $909.5M | $146.4M | ||
| Q2 24 | $1.0B | $119.9M |
股东权益NVAXROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-127.8M | $1.2B | ||
| Q3 25 | $-156.7M | $1.2B | ||
| Q2 25 | $37.6M | $1.2B | ||
| Q1 25 | $-75.6M | $1.3B | ||
| Q4 24 | $-623.8M | $1.3B | ||
| Q3 24 | $-526.4M | $1.3B | ||
| Q2 24 | $-431.7M | $1.3B |
总资产NVAXROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.8B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-39.5M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $-41.6M | $1.1M |
| 自由现金流率自由现金流/营收 | -28.2% | 0.5% |
| 资本支出强度资本支出/营收 | 1.4% | 2.3% |
| 现金转化率经营现金流/净利润 | -2.25× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $-250.2M | $70.1M |
8季度趋势，按日历期对齐
经营现金流NVAXROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-39.5M | $46.9M | ||
| Q3 25 | $107.8M | $28.9M | ||
| Q2 25 | $-127.5M | $13.7M | ||
| Q1 25 | $-185.5M | $11.7M | ||
| Q4 24 | $-87.3M | $33.7M | ||
| Q3 24 | $-144.8M | $42.4M | ||
| Q2 24 | $314.3M | $22.9M |
自由现金流NVAXROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-41.6M | $42.2M | ||
| Q3 25 | $105.8M | $21.2M | ||
| Q2 25 | $-127.7M | $5.6M | ||
| Q1 25 | $-186.7M | $2.1M | ||
| Q4 24 | $-100.3M | $18.3M | ||
| Q3 24 | $-146.2M | $25.2M | ||
| Q2 24 | $311.4M | $8.8M |
自由现金流率NVAXROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | -28.2% | 20.9% | ||
| Q3 25 | 150.2% | 9.8% | ||
| Q2 25 | -53.4% | 2.8% | ||
| Q1 25 | -28.0% | 1.1% | ||
| Q4 24 | -113.6% | 9.5% | ||
| Q3 24 | -173.0% | 12.0% | ||
| Q2 24 | 74.9% | 4.1% |
资本支出强度NVAXROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.4% | 2.3% | ||
| Q3 25 | 2.9% | 3.6% | ||
| Q2 25 | 0.1% | 4.0% | ||
| Q1 25 | 0.2% | 5.0% | ||
| Q4 24 | 14.8% | 8.0% | ||
| Q3 24 | 1.6% | 8.2% | ||
| Q2 24 | 0.7% | 6.6% |
现金转化率NVAXROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | -2.25× | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | -1.20× | — | ||
| Q1 25 | -0.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | 1.94× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NVAX
| Licensing Royalties And Other | $107.9M | 73% |
| Products | $39.2M | 27% |
ROG
暂无分部数据
